LINC02641: A Non-Coding RNA Molecule with Potential Drug Target and Biomarker Properties

Target Name: LINC02641

NCBI ID: G105378531

LINC02641

Other Name(s): LOC105378531 variant X4 | Uncharacterized LOC105378531, transcript variant X4 | long intergenic non-protein coding RNA 2641

LINC02641: A Non-Coding RNA Molecule with Potential Drug Target and Biomarker Properties

LINC02641 (LOC105378531) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. The molecule is derived from the gene Loc105378531, which is located on chromosome 6p21. LINC02641 is a small non-coding RNA molecule that is expressed in a variety of tissues and cells. It is characterized by a unique structure that consists of a series of 19 exons that are arranged in a specific order.

One of the key features of LINC02641 is its ability to interact with various transcription factors, including SV40122, UV404, and HIF1?±. These transcription factors are known to play important roles in regulating gene expression and are often involved in the development and progression of various diseases . By interacting with these transcription factors, LINC02641 is able to regulate the activity of genes that are involved in cell growth, differentiation, and survival.

Another important function of LINC02641 is its role in the regulation of cellular processes that are important for the development and progression of cancer. For example, LINC02641 has been shown to play a role in the regulation of the cell cycle, which is the process by which cells grow and divide. In cancer cells, the cell cycle is often out of control, and this can lead to the development of various cancerous behaviors. By regulating the cell cycle, LINC02641 may be able to inhibit the growth and survival of cancer cells.

In addition to its role in the regulation of the cell cycle, LINC02641 has also been shown to play a role in the regulation of cellular processes that are important for the development and progression of neurodegenerative diseases. For example, LINC02641 has been shown to interact with the neurotransmitter receptor GABA, which is involved in the regulation of a variety of cellular processes that are important for brain function. This interaction may be important for the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Furthermore, LINC02641 is also known to play a role in the regulation of cellular processes that are important for the development and progression of diseases that are characterized by inflammation and oxidative stress. For example, LINC02641 has been shown to interact with various transcription factors that are involved in the regulation of inflammation and oxidative stress. This interaction may be important for the development and progression of diseases that are characterized by inflammation and oxidative stress, such as rheumatoid arthritis and inflammatory bowel disease.

In conclusion, LINC02641 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its unique structure and ability to interact with various transcription factors make it an attractive target for Further study. Further research is needed to determine the full extent of LINC02641's role in the regulation of cellular processes and its potential as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2641

The "LINC02641 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02641 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets